Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 "Development of the proteasome inhibitor Velcade (Bortezomib)" by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D.

Literature DB >> 15199617

"Development of the proteasome inhibitor Velcade (Bortezomib)" by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D.

Richard Bold.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2004 PMID： 15199617 DOI： 10.1081/cnv-120030223

Source DB: PubMed Journal: Cancer Invest ISSN： 0735-7907 Impact factor: 2.176

Keyword Cloud
Cited

× No keyword cloud information.

13 in total

Review 1. The Emerging Role of Non-traditional Ubiquitination in Oncogenic Pathways.

Authors: Lisa Dwane; William M Gallagher; Tríona Ní Chonghaile; Darran P O'Connor
Journal: J Biol Chem Date: 2017-02-01 Impact factor: 5.157

2. Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis.

Authors: Joan Oliva; Samuel W French; Jun Li; Fawzia Bardag-Gorce
Journal: Exp Mol Pathol Date: 2012-03-16 Impact factor: 3.362

Review 3. Targeting biomolecules with reversible covalent chemistry.

Authors: Anupam Bandyopadhyay; Jianmin Gao
Journal: Curr Opin Chem Biol Date: 2016-09-10 Impact factor: 8.822

4. Lysine-Targeted Reversible Covalent Ligand Discovery for Proteins via Phage Display.

Authors: Mengmeng Zheng; Fa-Jie Chen; Kaicheng Li; Rahi M Reja; Fredrik Haeffner; Jianmin Gao
Journal: J Am Chem Soc Date: 2022-08-17 Impact factor: 16.383

5. A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.

Authors: Christopher Lieu; Laura Chow; A Scott Pierson; S Gail Eckhardt; Cindy L O'Bryant; Mark Morrow; Zung Vu Tran; John J Wright; Lia Gore
Journal: Invest New Drugs Date: 2008-07-11 Impact factor: 3.850

6. [USP33 suppresses lung adenocarcinoma lung cell invasion and metastasis by down-regulating SLIT2/ROBO1 signaling pathway].

Authors: Yuhuan Wang; Shuhua Zhang; Shukun Mu; Baishen Zhang; Shudong Ma
Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2018-07-30

"Development of the proteasome inhibitor Velcade (Bortezomib)" by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D.

Review 1. The Emerging Role of Non-traditional Ubiquitination in Oncogenic Pathways.

2. Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis.

Review 3. Targeting biomolecules with reversible covalent chemistry.

4. Lysine-Targeted Reversible Covalent Ligand Discovery for Proteins via Phage Display.

5. A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.

6. [USP33 suppresses lung adenocarcinoma lung cell invasion and metastasis by down-regulating SLIT2/ROBO1 signaling pathway].

7. K63-linked ubiquitination in kinase activation and cancer.

Review 8. Deubiquitinases and the new therapeutic opportunities offered to cancer.

9. Bortezomib treatment causes long-term testicular dysfunction in young male mice.

10. Clinical analysis of 40 multiple myeloma patients with extramedullary plasmacytoma of the head.